Status:
COMPLETED
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
Lead Sponsor:
French Innovative Leukemia Organisation
Conditions:
Diffuse Large B-Cell Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The primary objective of the protocol is to estimate the complete response rate of three courses of the association of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggres...
Detailed Description
Phase II study of the efficacy and toxicity of rituximab, navelbine, ifosfamide, mitoxantrone, and prednisone in relapsed aggressive non hodgkin's B-cell lymphoma. The study intervention is an admini...
Eligibility Criteria
Inclusion
- Both genders, between 18 and 75 years old
- CD 20+ large cell lymphoma
- In first relapse
- No previous autologous stem cell transplantation or relapsing more than 12 months after an autologous stem cell transplantation
- Ann Arbor stage I, II, III ou IV
- ECOG 0,1 or 2
- Signed informed consent
Exclusion
- age: before 18 and more than 75 years old
- other type of lymphoma
- Informed consent not signed
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00842595
Start Date
December 1 2003
End Date
May 1 2010
Last Update
July 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital COCHIN
Paris, France, 75014